Reviewer #3 (Public review):
Summary:
Tkacik et al. systematically characterized all three RAF kinase isoforms in vitro with all three types of RAF inhibitors (Type I, I1/2, and II) to investigate the mechanism underlying paradoxical activation.
In this study, the authors reconstituted heterodimers of A-, B-, and C-RAF kinase domains bound to non-phosphorylable MEK1 (SASA), mimicking the monomeric auto-inhibited state of RAF. These "RAF monomers" were tested for MEK phosphorylation with an increasing concentration of all three types of RAF inhibitors (Type I, I1/2, and II). This study is reminiscent of a previous study of the same team measuring RAF kinase activity in the presence of all three types of inhibitors in the context of dimeric RAF isoforms stabilized by 14-3-3 proteins (Tkacik et al 2025 JBC). RAF monomers had little to no activity at low concentrations of inhibitors (consistent with their "monomeric state"). Addition of type I1/2 inhibitor did not induce paradoxical activation as, in this context, they do not induce RAF dimerization required for activation, as observed by MP. Addition of type I and type II inhibitors led to paradoxical activation consistent with the RAF dimerization induced by these inhibitors, as observed by MP. Interestingly, type II inhibitors induced activation only for B- and C-RAF and not A-RAF.
At high concentrations of type II inhibitors, kinase activity is inhibited with a strong or weak positive cooperativity for BRAF and CRAF, respectively. This observation is very similar to what the authors previously observed with their dimeric RAF system. Interestingly, when the NtA motif is modified by phosphomimetic mutations in A- and C-Raf, basal kinase activity is stronger, but most importantly, inhibitor-induced paradoxical activation is much stronger with both type I and II inhibitors. This demonstrates that mutation of the NtA motif of ARAF and CRAF sensitized them to paradoxical activation by type II inhibitors.
The authors also tested the effect of ATP in the paradoxical activation observed in their RAF "monomer" system. As previously published in their assay with 14-3-3 stabilized dimeric RAF, the authors observed an expected shift of the IC50 with Type I inhibitors, while Type II inhibitors seem to behave as a non-competitive inhibitor. The authors next reconstituted the MAP kinase pathway (with RAF monomers at the top of the phosphorylation cascade) to test paradoxical activation amplification. Again, Type I1/2 inhibitors did not induce paradoxical activation, while Type I and II inhibitors did. The authors tested the inhibitors with FL auto-inhibited RAF/MEK/14-3-3 complexes, where, contrary to the "RAF monomers" experiments, FL B- and C-RAF were not paradoxically activated but were inhibited by all three types of inhibitors.
Overall, Tkacik et al. tackle an important question in the field for which definitive experiments and thorough biochemical investigation to understand the molecular mechanisms for the inhibitor-induced paradoxical activation are still missing, and of high importance for future drug development.
Strengths:
The biochemical experiments here are rigorously executed, and the results obtained are highly informative in the field to decipher the intricate mechanisms of RAF activation and inhibitor-induced paradoxical activation.
Weaknesses:
The interpretation of the results in the context of the current state of the art is ambiguous and raises questions about the relevance of introducing a new model for inhibitor-induced paradoxical activation, particularly since the findings presented here do not clearly contradict established paradigms. I believe some clarification and precision are required.
Main comments:
(1) Figure 2:
The authors comment on the expected greater increase (for a cascade assay) in the magnitude of ERK phosphorylation compared to what was observed for MEK phosphorylation. However, this observation might be reflective of the stoichiometries used in the assay, with 40 times more MEK compared to RAF concentration (250nm vs 6nM), which might favour pERK vs pMEK.
- The authors should clarify their rationale for the protein concentration used in this assay and explain how protein stoichiometry was taken into account for the interpretation of their results.
- In addition, the authors should justify comparing pMEK and pERK TR-FRET values when different anti-phospho antibodies were used. Antibodies may have distinct binding affinities for their epitopes. Could this not lead to differences in FRET signal amplitudes that complicate direct comparison?
(2) Supplementary Figure 2:
The author mentioned that the inhibitors did not activate the FL auto-inhibited RAF complexes; however, they did inhibit the TR-FRET signal.
- Can the authors comment on the origin of the observed basal activity? Would the authors expect self-release of the RAF kinase protein from the auto-inhibited state in the absence of RAS, leading to dimerization and activation? Alternatively, do the inhibitors at low-concentration relieve the auto-inhibited state, thereby driving dimerization and activation?
- Did the author test the addition of RAS protein in their in vitro system to determine whether "soluble" RAS is sufficient to release the protective interactions with RBD/CRD/14-3-3 and lead to inhibitor-induced paradoxical activation of FL RAF?
(3) Figure 5B:
The authors said that the Kd values obtained from their MP assay are consistent with prior studies of RAF homodimerization and RAF:MEK heterodimerization. While this is true from the previous studies of RAF:MEK interaction by BLI (performed from the same team), the Kd of isolated RAF kinase homodimerization has been measured around ~30µM by AUC in the cited ref (24,27 & 37).
- The authors should discuss the discrepancy between their Kd of homodimerization and the reported Kd values in the literature. At the concentration used for MP, it is surprising to observe RAF dimerization while the Kd of homodimerization has been measured at ~30µM (in the absence of MEK).
- Would the authors expect the presence of MEK to influence the homodimerization affinity for the isolated KD?
(4) Conclusions:
Several times in the introduction and the conclusion, the authors suggest that the negative allostery model (where "inhibitor binding to one protomer of the dimer promotes an active but inhibitor-resistant conformation in the other") is a model that applies to all types of RAF inhibitors (I, I1/2, and II).
However, from my understanding and all the references cited by the authors, this model only applies to type I1/2 inhibitors, where indeed the aC IN conformation in the second (inhibitor-free) protomer of the RAF dimer might be incompatible with the type I1/2 inhibitors inducing aC OUT conformation. The type I and type II inhibitors are aC IN inhibitors and are expected to bind both protomers from RAF dimers with similar affinities. Therefore, the negative allostery model does not apply to the type I and type II inhibitors. The difference in the mechanism of action of inhibitors is even used to explain the difference in the concentration range in which inhibitor-induced activation is observed in cells. The description of the state of the art in this study is confusing and does not help to properly understand their argumentation to revise the established model for paradoxical RAF activation.
- Can the authors clarify their analysis of the state of the art on the different mechanisms of action for the paradoxical activation of RAF by the different types of RAF inhibitors?
5) Conclusions:
"Our results suggest that negative allostery (or negative cooperativity) is not a requisite feature of paradoxical activation. The type I and type II inhibitors studied here induce RAF dimers and exhibit paradoxical activation but do so without evidence of negative cooperativity, nor do they appear to inhibit intentionally engineered RAF dimers with negative cooperativity (25). Indeed, type II inhibitors exhibit apparent positive cooperativity while type I inhibitors are non-cooperative inhibitors of RAF dimers (25)."
- Can the authors explain how results on the paradoxical activation induced by type I and type II inhibitors inform or challenge a model that specifically applies to type I1/2 inhibitors?
The authors often refer to their previous study (reference 25), where they tested the inhibition of all three types of inhibitors with engineered RAF dimers. While I agree with the authors that in reference 25 the Type I and type II inhibitors inhibit RAF dimers without exhibiting negative cooperativity (as expected from the literature and the current model), the authors did observe some negative cooperativity for Type I1/2 inhibitors in their study most particularly for the type I1/2 PB (with hill slope ranging from -0.4 to -0.9, indicative of negative cooperativity).<br />
While the observations that type II inhibitors display positive cooperativity is both novel and very interesting, from what I understand the results from thakick et al 2025 and the current study appear more in line with the current paradigm in the field (which describe paradoxical activation with negative cooperativity for type I1/2 inhibitors and no negative cooperativity for the Type I and II inhibitors) rather than disapproving of the current model and supporting for a new model.
- In this context, can the authors clarify how their results challenge the current model for paradoxical activation?
(6) Conclusions:
The authors describe the JAB34 experiment from Poulikakos et al. 2010 to conclude that "While this experiment cleanly demonstrates inhibitor-induced transactivation of RAF dimers, it is important to recognize that the differential inhibitor sensitivity of the two subunits in this experiment is artificial - it is engineered rather than induced by inhibitor binding as the negative allostery model proposes."
Indeed, the JAB34 experiment demonstrated the inhibitor-induced transactivation, but the Poulikakos et al. 2010 study does not discuss differential inhibitor sensitivity. The negative allostery model was proposed later by poulikakos team in other papers (Yao et al 2015 and Karoulia et al, 2016), in which JAB34 was not used.
- Can the authors clarify how the JAB34 experiments question differential inhibitor sensitivity?
(7) Conclusions:
"Considering that the conformation required for binding of type I.5 inhibitors destabilizes RAF dimers, it is unclear how an inhibitor binding to one protomer would be able to transmit an allosteric change to the opposite protomer, if that inhibitor's binding causes the existing dimer to dissociate."
- The authors should comment on whether 14-3-3 proteins might overcome negative regulation by type I1/2 inhibitors, similar to what has been shown for ATP, which acts as a dimer breaker like type I1/2 inhibitors.
(8) Conclusions:
"Furthermore, the complex effects of type I.5 inhibitors on dimer stability and the clear resistance of active RAF dimers to these inhibitors complicates interpretation of inhibition data - weak or incomplete inhibition of an enzyme can be difficult to discern from true negative cooperativity (43). As we discuss below, the clear resistance of RAF dimers to type I.5 inhibitors is alone sufficient to explain their ineffective inhibition during paradoxical activation, without invoking negative allostery."
- The authors should explain how they reconcile this statement and their proposal of a new model that does not rely on negative allostery with their previous findings showing negative cooperativity for RAF dimer inhibition with type I1/2 inhibitors.
(9) Conclusions:
Here, the authors propose a new universal model to explain paradoxical activation of RAF by all types of RAF inhibitors:<br />
" Our findings here, in light of structural studies of RAF complexes and prior cellular investigations of paradoxical activation, lead us to a model for paradoxical activation that does not rely on negative allostery and is consistent with activation by diverse inhibitor classes. In this model, the open monomer complex is the target of inhibitor-induced paradoxical activation (Figure 6). Binding of ATP to the RAF active site stabilizes the inactive conformation of the open monomer, which disfavors dimerization. Displacement of ATP by an ATP-competitive inhibitor, irrespective of class, alters the relative N- and C-lobe orientations of the kinase to promote dimerization (30, 35). Once dimerized, inhibitor dissociation from one or both sides of the dimer would allow phosphorylation and activation of MEK."
From my understanding, the novelty of this new model is twofold: a) the open monomer is the target of the inhibitor-induced paradoxical activation and b) once dimerized, inhibitor dissociation from one or both sides of the dimer would allow phosphorylation and activation of MEK.
Novelty a) implies, as the authors stated, that "Inhibitor-induced activation and inhibition act on distinct species - activation on the open monomer and inhibition on the 14-3-3-stabilized dimer". The authors should explain what they mean by "activation of the open monomer", while only RAF dimers are catalytically active (except for BRAF V600E mutant)?
For novelty b), the authors should explain more clearly what experimental results support this new model.